Intra Cellular Therapies | ITCI - Дебиторская задолженность



Дебиторская задолженность Изменить Дата
Acadia Pharmaceuticals USD 148.38M 153K 2026-03
ALKERMES USD 407.63M 73.6M 2026-03
BioCryst Pharmaceuticals USD 106.82M 15.49M 2025-12
Biogen USD 1.79B 76.6M 2026-03
Bristol-Myers Squibb USD 14.36B 164M 2026-03
Cytokinetics USD 6.83M 10.94M 2026-03
Esperion Therapeutics USD 140.19M 21.21M 2025-12
Gilead Sciences USD 4.74B 172M 2026-03
Halozyme Therapeutics USD 457.99M 16.72M 2026-03
J&J USD 21.33B 3.72B 2025-12
Nektar Therapeutics USD 1.78M 1.12M 2025-12
Neurocrine Biosciences USD 768.1M 81.3M 2026-03
Novartis USD 12.29B 3.3B 2025-12
Prothena USD 5.16M 0 2023-12
RedHill Biopharma USD 5.35M 1.78M 2025-06
Supernus Pharmaceuticals USD 182.18M 5.62M 2026-03
United Therapeutics USD 312M 38.2M 2026-03
Vanda Pharmaceuticals USD 47.1M 4.35M 2024-12